Opioid agonist therapy (OAT), including methadone, buprenorphine/naloxone (i.e., Suboxone), and Kadian, is the most effective treatment for opioid use disorder. During the COVID-19 pandemic, guidelines for OAT were developed with a focus on with a focus on making it easier to reduce contact with others, while still allowing those in need to access to OAT.
The goal of this study is to explore the experiences of OAT prescribers and clients on OAT during the COVID-19 pandemic (March 17, 2020 and onward). You will be asked to complete one 15-30 minute online survey. You will be eligible to receive your choice of one $15 gift card (either Walmart, PC, Tim Horton’s, or Ultimate Dining Card) as a thank you for your time. It may take up to three weeks to process your compensation.
FOR CLIENTS: Online at https://form.simplesurvey.com/f/l/OATclient
FOR PRESCRIBERS: Online at https://form.simplesurvey.com/f/l/OATPrescriber
Kim Corace, PhD